Authors

Latest:

Dr Phillips on the Use of Bispecific Antibodies and CAR T-Cell Therapy in MCL and FL

Tycel Phillips, MD, MPH, discusses the use of bispecific antibodies and CAR T-cell therapy across hematologic malignancies, including in patients with mantle cell lymphoma and follicular lymphoma.

Caroline Piatek, MD

Latest:

Key Takeaways From Discussion

Physicians share key takeaways from the discussion on diagnosis and treatment of immune thrombocytopenia.

The Association of Community Cancer Centers

Latest:

ACCC Welcomes Matt Devino, MPH, as Director, Cancer Care Delivery and Health Policy

The Association of Community Cancer Centers announced that Matt Devino, MPH has joined the organization as Director, Cancer Care Delivery and Health Policy.

Jaspal Singh, MD, MHS

Latest:

Looking Ahead: Treatment Advancements and Multidisciplinary Perspectives on the Future of Early-Stage NSCLC Care

Panelists discuss how medical professionals envision the future of early-stage non–small cell lung cancer (NSCLC) treatment evolving through the integration of novel therapies, predictive biomarkers, and personalized strategies to address current gaps in care, emphasizing the need for continued research to optimize outcomes and tailor interventions in resectable disease.

Ossama Tawfik, MD

Latest:

Role of a Pharmacist in Developing Treatment Pathways and Educating Patients

Ryan Haumschild, PharmD, MS, MBA, reflects on how oncologic pharmacists can help to develop treatment pathways and educate patients on precision medicine.

Maxine Sun, PhD, MPH

Latest:

Dr Sun on Ongoing Research Efforts Examining Clonal Hematopoiesis in RCC

Maxine Sun, PhD, MPH, discusses ongoing research efforts dedicated to examining the relationship between clonal hematopoiesis and cardiovascular disease in patients with renal cell carcinoma.

Kristin Higgins, MD, City of Hope

Latest:

Multidisciplinary Management of Locoregional Non–Small Cell Lung Cancer

Matthew A. Steliga, MD

Latest:

Smoking Cessation Support Plays a Vital Role in Improving Lung Cancer Screening

Results of the National Lung Screening Trial demonstrated a 20% decrease in lung cancer mortality in individuals aged 55 to 74 years with a 30 pack-year smoking history using a low-dose computed tomography scan.

Dennis L. Cooper, MD

Latest:

CAR T-Cell Therapy for Multiple Myeloma: Eliminating Disparities Through Accountability

Although the first FDA approval for CAR T-cell therapy in multiple myeloma was 2 years ago, unfortunately, the treatment remains out of reach for too many patients.

Prateek Gulhati, MD, PhD

Latest:

Dr. Gulhati on Current Treatment Approaches in Pancreatic Cancer

Prateek Gulhati, MD, PhD, discusses current treatment approaches in pancreatic cancer and strategies under investigation within the space.

Sabrina Serani

Latest:

Adjuvant Aromatase Inhibition Is Associated With Improved DFS, TTDR in HR+/HER2+ Breast Cancer

Adjuvant AI therapy improved DFS and TTDR vs a SERM in patients with hormone receptor–positive, HER2-positive early breast cancer.

Reva K. Basho, MD

Latest:

Dr Basho on Treatment Considerations With ADCs in Breast Cancer

Reva K Basho, MD, discusses the use of antibody-drug conjugates across the spectrum of breast cancer subtypes at the 2023 Bridging the Gaps in Breast Cancer meeting.

Axel Merseburger, MD, PhD

Axel Merseburger, MD, PhD, is a professor of urology and chairman of the Department of Urology at University Hospital Schleswig Holstein, Campus Lübeck.

Latest:

Dr Merseburger on Real-World Avelumab/Axitinib Discontinuations in Advanced RCC

Axel Merseburger, MD, PhD, discusses AEs associated with real-world treatment discontinuations of avelumab plus axitinib in advanced renal cell carcinoma.

Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center

Latest:

Metastatic Colorectal Cancer: Ongoing Challenges and Future Directions in Care

Closing out their panel on metastatic colorectal cancer, expert oncologists consider ongoing challenges and future evolutions within the treatment landscape.

J. Bradley Elder, MD

Latest:

Dr Elder on the Initial Safety Profile of IGV-001 in Newly Diagnosed Glioblastoma

J. Bradley Elder, MD, discusses blinded early-safety data from a phase 2b trial of IGV-001 in patients with newly diagnosed glioblastoma.

Michael Serzan, MD

Latest:

Dr Serzan on the Rationale for Evaluating Botensilimab Plus Balstilimab in Advanced RCC

Michael Serzan, MD, discusses the rationale for evaluating botensilimab/balstilimab for patients with advanced renal cell carcinoma.

Richard Martin, MD, MPH

Latest:

Mentoring Oncologists in the Era of Social Distancing

Mentoring is critically important to the development of young academic hematology/oncology trainees.

Masahiro Tsuboi, MD, National Cancer Center Hospital East

Latest:

Dr Tsuboi on Updated Survival Results of the ADAURA Trial in Resectable NSCLC

Masahiro Tsuboi, MD, discusses the updated survival results of the phase 3 ADAURA trial in resectable EGFR-mutant non–small cell lung cancer.

Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute

Latest:

Novel Treatment Combinations in Chronic Lymphocytic Leukemia

Dr Brown and Dr Stilgenbauer provide their input on novel treatment options emerging for chronic lymphocytic leukemia.

Riley Kandel

Latest:

Real-World Data Showcase Efficacy of Adjuvant Pembrolizumab in ccRCC

Pembrolizumab in the adjuvant setting yielded high DFS and OS results in addition to a manageable safety profile in real-world patients with ccRCC.